Investigational treatment studies for mild COVID.
COVID-19
POSITIVE.
TIME FOR SWIFT
Action.
Research studies are enrolling today!
We are looking for participants to join investigational treatment studies for mild COVID. Those who qualify may receive:
- Payment up to $3,800
- Study-related care at no cost from local doctors
- No-cost, easy to take investigational nasal spray or placebo (a treatment that looks like the investigational medicine with no active properties)
If you’re at low risk of severe illness, see if you qualify.
COVID-19 has changed into an ordinary illness. Help medicine change with it.
After a long and extremely difficult 3 years, COVID no longer qualifies as a global emergency.
However, the virus is still highly contagious and still infecting people worldwide.
You don’t have to be at high risk of severe illness for COVID to affect your life and the lives of those around you. Isolation is recommended, but living spaces and circumstances may not allow it. Also, research suggests that mild COVID may raise the risk of long COVID.
We need more treatment options.
You can do something.
Doctors and specialists are leading research studies to learn about the effect of investigational nasal spray on mild COVID. No pills to swallow! The spray is easy to take and convenient. And the treatment period is short: Just 3 days.
To qualify, you must meet the following criteria:
- Be between the ages of 18 and 64
- Show signs of at least least one mild or just noticeable symptom,
such as:
- Sore throat
- Sneezing and/or cough
- Stuffy or runny nose
- Shortness of breath
- Body aches
- Tiredness
- Fever or feeling hot
- Loss of taste or smell
- Test positive for COVID*
*You will be referred to a study site to confirm that you are eligible for participation in this study.
Individuals who choose to participate in the study will not be charged for the study treatment or study-related care. Health insurance is not needed.
How does it work?
Answer some questions
about your health
If you qualify to participate,
our staff will reach out to you
Qualified individuals will be directed to
a clinical site at a preferred location
©2023 Acurian, Inc. All rights reserved.